Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.
about
Pharmaceutical particle engineering via spray drying.Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery.Selective targeting of alveolar type II respiratory epithelial cells by anti-surfactant protein-C antibody-conjugated lipoplexesFormulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken designAdvances in biomimetic regeneration of elastic matrix structures.Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanopartiCubic magnetically guided nanoaggregates for inhalable drug delivery: in vitro magnetic aerosol deposition studyElectrospraying, spray drying and related techniques for production and formulation of drug nanoparticles.Strategies for non-invasive delivery of biologics.Supercritical CO₂-Assisted Spray Drying of Strawberry-Like Gold-Coated Magnetite Nanocomposites in Chitosan Powders for Inhalation.Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery.Dry powder inhalation: past, present and future.Bovine serum albumin adsorbed PGA-co-PDL nanocarriers for vaccine delivery via dry powder inhalation.Particle formation and capture during spray drying of inhalable particles.Recent advances in therapeutic delivery systems of bacteriophage and bacteriophage-encoded endolysins.Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration.Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.Chitosan-genipin nanohydrogel as a vehicle for sustained delivery of alpha-1 antitrypsin.Cellular antiendotoxin activities of lung surfactant protein C in lipid vesicles.Development of low density azithromycin-loaded polycaprolactone microparticles for pulmonary delivery.Microparticles for inhalational delivery of antipseudomonal antibiotics.Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients.Preparation, optimization, and in vitro simulated inhalation delivery of carvedilol nanoparticles loaded on a coarse carrier intended for pulmonary administration.Respiratory delivery of theophylline by size-targeted starch microspheres for treatment of asthma.Towards a more desirable dry powder inhaler formulation: large spray-dried mannitol microspheres outperform small microspheres.Investigation of the physical properties of spray-dried stabilised lysozyme particles.The preparation and application of pulmonary surfactant nanoparticles as absorption enhancers in insulin dry powder delivery.Sustained delivery of salbutamol and beclometasone from spray-dried double emulsions.Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery.Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.A novel method to aerosolize powder for short inhalation exposures at high concentrations: isolated rat lungs exposed to respirable diesel soot.Low gas permeability of particulate films slows down the aging of gas marbles.Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals.Optimization of formulation components and characterization of large respirable powders containing high therapeutic payload.Preparation, characterization and pulmonary pharmacokinetics of a new inhalable zanamivir dry powder.Making large, flowable particles of protein or disaccharide in a mini-scale spray dryer.Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance.Co-spray dried carbohydrate microparticles: crystallisation delay/inhibition and improved aerosolization characteristics through the incorporation of hydroxypropyl-β-cyclodextrin with amorphous raffinose or trehalose.Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering.
P2860
Q30496354-536C0192-8B96-4324-A465-43CDAF6B6CBEQ34061809-259B8542-A17D-4067-A911-8BED4BD21374Q35434883-0CEB58F8-323B-4A2E-A7EE-7AF23D4C6602Q35796474-43E859C7-8A89-450F-B41D-3DBD226F56B1Q36552037-5F57710A-5DE0-4F75-BC46-1B851AC44422Q36555371-000A8235-B83C-47C1-A080-DFA67BA8282EQ37126447-A3976BC1-214C-4962-BE97-6DD9027BBC4BQ37719548-99331140-B7DB-4DBE-AFCA-878AF73B3BF2Q38013190-FA4F8C78-F51B-48E4-AD1E-40261E31AC50Q38647454-1B0AF53A-AF3D-4FB9-BDDE-630819B66947Q38714479-35802459-AC93-4E5E-AAA0-3D5798BDF8F8Q38830375-B537660E-C76A-4E4A-9437-355FD5E9C0DCQ38949613-C9A2CEDE-2A02-4242-8A5A-FF8EC077708DQ39129408-EA013D88-66EE-4475-99E0-C74D132CC4A0Q39386520-67565F24-7A0C-462A-89E2-52269D3D1BD1Q39562651-5B9C2129-8379-4E64-9CC8-FFD007BDBD08Q39856908-84331BD7-91DB-4849-9308-3B7DF6E7F8FAQ40058358-4A367AFE-620C-4D9A-9DDD-6031755463E7Q40095457-1C3ED37F-967B-4437-B541-ABB027EFC4C7Q40644191-341CC325-CC03-4D86-8A04-9E650D5E060BQ41043744-1CA367B4-1908-4CE0-98BE-EB3B5B034005Q41843336-63236107-34BC-4E97-8042-0493D2B8E04DQ42909622-2033E1E1-8337-44C8-A9DD-09A4037032A6Q43216548-F66D9F1D-3E5A-4D05-B48A-FA0F2CC70D03Q43248720-189D8AEF-C23C-41B9-BA7F-205053F7C0E8Q43614136-2AE9F7B4-0DAE-4BA1-BF4E-E7C9E0EECC52Q44646545-F6507434-F6FB-421C-BD2F-E781DDE0EE49Q45916817-E2ABB3EA-E871-479C-B71E-F4C09DA594FEQ45963408-95133743-E0ED-436B-8D45-98E3F9311B55Q45974678-91C57D35-65DB-44BF-A0B0-A9C7DC6996A4Q46145077-D28BA81C-880F-4F6C-B2B2-AF950F8A6205Q47241246-928DD25F-FB0E-4257-8999-3D2D0D6A8C54Q49560753-9C0E3D80-5D11-4009-B799-DF549921B951Q50899972-609164CA-7C45-45DA-B535-D97A590A500FQ51105104-7AB8DB97-C542-4354-B8CC-3808E5AED80EQ53210787-E576D9F8-F804-472F-B3B8-749955D7243DQ53443922-7C23AC89-412C-4551-98FC-6689F1EB1D73Q53446106-F356BBCA-8B1E-4D82-9789-8D191B80E6B9Q53487456-65E0CBC5-3D65-4874-8057-C621D8226D42Q55250317-7F30999B-0547-4548-964C-A1DCEB42B03D
P2860
Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Influence of formulation excip ...... ir aerosolization performance.
@ast
Influence of formulation excip ...... ir aerosolization performance.
@en
type
label
Influence of formulation excip ...... ir aerosolization performance.
@ast
Influence of formulation excip ...... ir aerosolization performance.
@en
prefLabel
Influence of formulation excip ...... ir aerosolization performance.
@ast
Influence of formulation excip ...... ir aerosolization performance.
@en
P2093
P1476
Influence of formulation excip ...... ir aerosolization performance.
@en
P2093
P304
P356
10.1016/S0168-3659(00)00362-X
P407
P577
2001-02-01T00:00:00Z